Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

PREDICTION OF ALZHEIMER’S DISEASE USING AN AI DRIVEN SCREENING PLATFORM

Project description

Spotting dementia early

Early treatment of Alzheimer’s disease and related dementias offers the best chance to slow progression. But most healthcare systems are still unprepared for the shift towards much earlier detection. The EU-funded PREDICTOM project aims to build an open-source, interoperable biomarker screening platform that brings diagnostics much closer to the patient. Using home-collected samples such as finger-prick blood, saliva, and stool, alongside innovative technologies such as MRI, EEG, eye tracking, and digital tools, the project will identify those at high risk. AI tools will be used to integrate biomarker data to guide personalised interventions. By creating scalable, cost-efficient screening and informing new clinical guidelines, PREDICTOM hopes to ease the personal and financial burden of dementia across Europe and beyond.

Objective

Alzheimer’s disease (AD) and related disorders leading to dementia are associated with staggering costs and suffering. Recently, there has been some progress in the search for effective therapeutic interventions and it is clear that any treatment is likely to be most effective if administered at the earliest stage of disease, but the health care system is not ready for this new scenario. There is an urgent need, therefore, to establish scalable, cost-efficient diagnostic markers, tools and procedures that can identify people at increased risk, at point of care for stratification into personalized interventions to prevent or delay dementia. PREDICTOM will develop an open-source, interoperable and customisable biomarker screening platform, utilizing an existing online resource to save time and money, to generate an evidence base for general population screening for AD and related disorders. We will bring diagnostics closer to the patient by examining the feasibility of using samples which can be obtained at home (e.g. finger-prick blood, saliva (for genetics and epigenetics) and stool for microbiom) for diagnostic biomarker analysis. We will also evaluate innovative technologies for disease risk identification, including digital technologies and novel MRI, EEG, eye tracking, and blood-based biomarkers. The platform will use artificial intelligence models to analyse data from all biomarkers to identify users at high risk of developing dementia and to direct them to personalized intervention to prevent further cognitive decline and development of dementia. We will seek to facilitate a change in current healthcare practice for early diagnosis of AD through development of new clinical practice guidelines based on evidence generated in the project. By improving the ease of identification of those with early signs of dementia we expect to have a significant impact on personal and financial burden of dementia in Europe and across the world.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-IHI-2022-03-single-stage

See all projects funded under this call

Coordinator

HELSE STAVANGER HF
Net EU contribution
€ 1 175 875,00
Address
GERD RAGNA BLOCH THORSENS GATE 8
4011 Stavanger
Norway
Region
Norge Vestlandet Rogaland
Activity type
Other
Links
Total cost
€ 1 525 875,00

Participants (30)

Partners (6)